Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLOW: semaglutide versus placebo for chronic kidney disease progression in adults with type 2 diabetes
MOH_2019-03-03_004918Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial in chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) comparing Semaglutide with Placebo (2 arms). Started Feb 2019; status: completed.
02
Drugs
03
Conditions
chronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on MOH_2019-03-03_004918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-03-03_004918.